Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction
Catheter Infections, End-stage Renal Disease
About this trial
This is an interventional prevention trial for Catheter Infections focused on measuring Catheter, Dysfunctions, Blood Stream Infections, Haemodialysis, Taurolidine, Tunneled
Eligibility Criteria
Inclusion Criteria:
- Adult patients aged greater than 18 years.
- Written informed consent.
- Requirement for haemodialysis using a tunneled dialysis catheter.
Exclusion Criteria:
- Children aged less than 18 years.
- Positive blood culture in previous seven days before catheter insertion.
- Heparin induced thrombocytopenia and any contraindication for anticoagulation (recent or planned surgery, thrombocytopenia < 70G/l, bleeding disorder).
Sites / Locations
- Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Control
Test
Non-systemic intraluminal application of 4% citrate lock solution (CitraFlow™ 4%, MedXL, Montreal, Canada) 3 times per week after dialysis.
TauroLock™ based lock solution regimen: Non-systemic intraluminal application of TauroLock™-Hep500, Tauropharm, Waldbüttelbrunn, Germany, 2x/week after dialysis (before short intervals) and TauroLock™-U25.000, Tauropharm, Waldbüttelbrunn, Germany, 1x/ week after dialysis (before long interval). TauroLock™-Hep500 contains 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin. TauroLock™-U25.000 contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase.